Mode
Text Size
Log in / Sign up
Phase 2 Completed N=120 Randomized Double-blind Treatment

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

Source: ClinicalTrials.gov NCT01906008 ↗
Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcomePrimary: Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months — 35.4; 31.5 Units on a scale *days

Summary

The goal of this clinical research study is to learn if minocycline can reduce numbness, pain, and/or loss of motor function in patients with colorectal cancer. In this study, minocycline will be compared to a placebo. The study doctor can explain how the study drug is designed to work. A placebo is not a drug. It looks like the study drug, but it is not designed to treat any disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect.

Outcome Measures

OutcomeResultp-value
PRIMARY
Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months
35.4; 31.5
SECONDARY
Average Area Under the Curve (AUC) for Fatigue Over 4 Months
47.92; 40.31

Eligibility Criteria

Inclusion Criteria

  • Patients with a pathologically proven diagnosis of CRC seen either at MD Anderson or LBJ.
  • Patients > or = 18 years old.
  • Patients who qualify for oxaliplatin-based chemotherapy (in the adjuvant or metastatic setting) and are likely to receive at least 3 months of oxaliplatin.
  • Patients who speak English or Spanish (due to language options for the MDASI version being used in this study, we are only recruiting English-speaking or Spanish-speaking patients).
  • Patients with an NCI-CTCv4 sensory neuropathy score of 0.
  • Patients with adequate renal function (serum creatinine must be 40 (Obese Class III criteria).
  • Patients who will receive cetuximab or other targeted therapy where physicians may use topical doxycycline to reduce the rash associated with therapy.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01906008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search